Breaking News

Trials & Filings in Brief: Sept. 27, 2013

By Gil Roth | September 27, 2013

CSL Behring, Durata, Novartis, Zalicus

CSL Behring's Hizentra cleared to treat PID in Japan . . . read more

Durata files NDA for ABSSSI treatment . . . read more

Zalicus gets orphan designation for Z160 . . . read more

Good data for Novartis' Lucentis . . . read more

Related Compliance:

blog comments powered by Disqus
  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.

  • Getting Real

    Michael Pollock, PPD||November 17, 2015
    Partnering for clinical and real-world evidence studies